Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Replimune Group, Inc. is a biotechnology company specializing in oncolytic immunotherapy for cancer treatment. Its proprietary RPx platform uses engineered herpes simplex virus to activate immune responses against tumors, aiming to improve efficacy and safety. The company develops virus-based therapies, including RP1, RP2, and RP3, targeting skin cancers, melanoma, and other tumor types, often in combination with immune checkpoint inhibitors, to enhance anti-tumor immunity.
This description was generated via AI from an annual report. Updated about 1 year ago.